Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-02-04

Clinical Trial Update: Circulating NEP and NEP Inhibition Study in Heart Failure With Preserved Ejection Fraction [Phase 4]

View source ↗

Summary

Phase 4 trial update on circulating NEP and NEP inhibition in heart failure with preserved ejection fraction (HFpEF).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Snippet

Sponsor: Mayo Clinic | Conditions: Heart Failure With Preserved Ejection Fraction | Phase 4 | Status: COMPLETED | Results posted: 2022-02-04